Stay updated with breaking news from Prospera Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics ...
Operator: Welcome to Natera’s 2023 Second Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode.
/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived...
/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cfDNA) testing, announced the completion...
AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cfDNA) testing, announced the completion of the VALID